ArticleFrontiers in microbiology2026
A fully integrated sample-to-answer molecular diagnostic platform for rapid identification of four major
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Invasive pulmonary aspergillosis (IPA) is more common among immunocompromised patients. Timely diagnosis is crucial but is challenging because current diagnostic approaches are often limited by low sensitivity, prolonged turnaround times, and technical complexity. Here, we developed a fully automated, real-time PCR-based, sample-to-answer molecular diagnostic platform for the simultaneous identification of four major Materials and methods: The sample-to-answer workflow was optimized using artificial bronchoalveolar lavage (BAL) samples spiked with Results: The assay demonstrated 95.2% (20/21) overall agreement with MALDI-TOF for culture isolates, achieving 93.3% positive agreement and 100% negative agreement. In the feasibility validation using 22 patient BAL samples including 11 proven and 11 probable IPA cases, the platform detected 10 out of 11 proven IPA samples (90.9%) with 100% species-level consistency with MALDI-TOF results. Notably, this assay could add mycological evidence in 3 of 11 culture-negative probable IPA cases. Conclusion: This fully automated, sample-to-answer platform enables rapid and accurate species-level identification of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.